A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson’s Disease (LRRK2-PD)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513384-15-00

Acronym

DNLI-C-0009

Enrollment

Registered

2024-11-25

Start date

2025-02-13

Completion date

Unknown

Last updated

2024-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson’s disease

Brief summary

Incidence of TEAEs and SAEs with BIIB122 compared with placebo over the 12-week double-blind period

Detailed description

Change from baseline in whole-blood pS935 LRRK2 with BIIB122 compared with placebo at Week 12, Change from baseline in urine BMP with BIIB122 compared with placebo at Week 12

Interventions

DRUGPlacebo to BIIB122

DRUGBIIB122

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence of TEAEs and SAEs with BIIB122 compared with placebo over the 12-week double-blind period	—

Secondary

Measure	Time frame
Change from baseline in whole-blood pS935 LRRK2 with BIIB122 compared with placebo at Week 12, Change from baseline in urine BMP with BIIB122 compared with placebo at Week 12	—

Countries

Germany, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026